Clinical trial shows safety and immunogenicity of temperature-stable experimental TB vaccine

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

Related Keywords

Christopherb Fox ,Danielf Hoft ,Emily Henderson ,Nature Communications ,School Of Medicine ,National Institute Of Allergy ,National Institutes Of Health ,Access To Advanced Health Institute ,Infectious Disease Research Institute In Seattle ,Saint Louis University Center ,Vaccine Development ,National Institute ,Infectious Diseases ,National Institutes ,Advanced Health Institute ,Infectious Disease Research Institute ,Discovery Industry Focus ,Immune Response ,Vaccine ,Allergy ,Antibodies ,Bacteria ,Clinical Trial ,Electron ,Immune System ,Medical Research ,Micrograph ,Mh ,Research ,Tuberculosis ,